Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

HIMS, DLO, and TEM combine high short interest with bullish chart setups, creating strong breakout potential as market momentum stays hot.

Topics Artificial Intelligence Supply Chain

3 Big Short Interest Names with Bullish Setups ↗

September 22, 2025

Via MarketBeat

Topics Artificial Intelligence

Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy ↗

September 21, 2025

Hims & Hers Health posted 73% revenue growth and 31% more subscribers in Q2. With analyst targets hitting $68, is now the time to buy HIMS?

Via MarketBeat

Topics Economy

Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

September 19, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.5% in the morning session after investors focused on the company's strong growth prospects, which appeared to overshadow recent...

Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened ↗

How Is The Market Feeling About Hims & Hers Health? ↗

September 18, 2025

Via Benzinga

September 16, 2025

Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown.

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds ↗

September 19, 2025

Via Benzinga

The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors. ↗

September 19, 2025

Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting.

Via Investor's Business Daily

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Via Benzinga

Topics ETFs

Hims & Hers Health's Options Frenzy: What You Need to Know ↗

September 17, 2025

Via Benzinga

2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now ↗

September 17, 2025

These dividend payers cranked up their payouts over the past decade, and they could do it again.

US markets closed slightly lower on Tuesday as investors waited for the Fed’s rate decision. Strong retail sales weren’t enough to lift the market, while several standout stock moves, from Steel...

Wall Street Waits on the Fed, but Steel and Semaglutide Steal the Show ↗

September 17, 2025

Via Chartmill

Topics Economy

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗

September 16, 2025

A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) sent the company a warning letter regarding “false or...

Topics Economy Stocks

Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why

September 16, 2025

BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today ↗

September 16, 2025

FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days.

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy ↗

September 16, 2025

Via Benzinga

FDA Slams Hims & Hers With A Warning Letter. Investors Slam Hims Stock. ↗

September 16, 2025

The company is best-known for its compounded weight-loss drugs. But those could be in trouble.

Via Investor's Business Daily

Huge News for Hims & Hers Stock ↗

September 16, 2025

Testosterone could be a huge growth market for Hims & Hers.

The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 55.7%, hitting $54 per share. This run-up might have investors contemplating their...

Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q2 Earnings?

September 16, 2025

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks ↗

September 13, 2025

FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA...

Via Benzinga

Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

September 12, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the...

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗

Topics Artificial Intelligence

September 12, 2025

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

3 Cash-Producing Stocks on Our Watchlist

September 12, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone...

Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

September 11, 2025

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.

Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone ↗

September 10, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market.

Why Hims & Hers Health (HIMS) Stock Is Trading Up Today

September 10, 2025

The company is making a move into a highly anticipated area and partnering with a privately held pharmaceutical company.

Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone ↗

September 10, 2025

Via Investor's Business Daily

Topics ETFs

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence ↗

September 10, 2025

Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows.

Via Benzinga

Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments

September 10, 2025

From Hims & Hers

Via Business Wire

Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow ↗

September 09, 2025

The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause.